Related Experiment Video
Updated: Jul 20, 2026
06:04
Surgical Treatment for Benign Prostatic Hyperplasia: Holmium Laser Enucleation of the Prostate (HoLEP).
Published on: March 6, 2018
Prevention of benign prostatic hyperplasia disease
Leonard S Marks1, Claus G Roehrborn, Gerald L Andriole
1Urological Sciences Research Foundation and Department of Urology, Geffen School of Medicine, University of California-Los Angeles, Los Angeles, California 90232, USA. lsmarks@ucla.edu
The Journal of Urology
|September 6, 2006
Summary
Benign prostatic hyperplasia (BPH) is a progressive condition. Men at risk can be identified by prostate-specific antigen levels and prevented with medication, regardless of symptoms.
Area of Science:
- Urology
- Gerontology
- Pharmacology
Background:
- Benign prostatic hyperplasia (BPH) is a common, age-related condition affecting the prostate.
- BPH can lead to significant lower urinary tract symptoms and complications, impacting quality of life.
- While prostate tissue changes are inevitable with aging, BPH disease progression is predictable and preventable.
Purpose of the Study:
- To review evidence on benign prostatic hyperplasia (BPH) progression.
- To identify men at risk for BPH disease.
- To assess the potential for treatment and prevention of BPH regardless of symptom status.
Main Methods:
- Systematic review of MEDLINE database.
- Searched for evidence on BPH progression, complications, risk factors, and medical prevention.
- Focused on predictive factors and their relation to disease progression and morbidity.
Main Results:
- BPH disease progression is linked to increased prostate volume and serum prostate-specific antigen (PSA) levels (excluding prostate cancer).
- PSA levels greater than 1.5 ng/ml are a key predictor of BPH disease morbidity, more so than baseline symptoms or flow rate.
- Benign prostatic hyperplasia disease is predictable and preventable, even in men without significant symptoms.
Conclusions:
- Men with PSA levels > 1.5 ng/ml are identified as at risk for BPH disease progression.
- 5-alpha-reductase inhibitors show potential for preventing BPH disease in at-risk men, irrespective of their current symptom severity.
Related Concept Videos
01:20Disorders of the Male Reproductive System
Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra. Symptoms...
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra. Symptoms...
01:22Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers
α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally, α1-blockers effectively address urinary obstruction...
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally, α1-blockers effectively address urinary obstruction...
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
01:30Preventive Healthcare Services
Preventive healthcare services keep people healthy via frequent check-ups, screening, and counseling. They primarily aid in disease prevention rather than treating an acute or chronic illness. Preventive treatment also keeps individuals productive and energetic, allowing them to work well into their retirement years. Examples of preventive care services include:
02:59Cancer Prevention
Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...
Some...
01:26Coronary Artery Disease IV: Preventive Measures
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...